Herald writers Wilson Moore, Tom Shatel, Ben Doody and Sam McKewon assess Nebraska basketball's stock heading back into Big ...

The drug targets a specific mutation that applies to only 2% of ALS patients. A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS ...

Over the last few years, research has been published showing a potential link between the shingles vaccine and a lower risk for dementia. Research published in April 2025 found that people receiving ...

The shingles vaccine could slow the progress of dementia, according to a new study from Stanford. These findings follow previous research that found older adults who received the vaccine were 20% less ...

Over 6 million Americans live with dementia, a progressive condition that affects memory, reasoning, judgment and language skills. There is no known cure for dementia, but new research suggests that a ...

SPRINGFIELD, Mo. (KY3) - Myopia or nearsightedness is a common vision problem that often begins between the ages of 6 and 14. Contacts or glasses can usually correct it, but new specialized lenses ...

Many of the world’s biggest businesses are making slow progress on their Net Zero goals and plans to deal with global warming, according to a new analysis. According to the latest EY Global Climate ...

November is Alzheimer’s Awareness Month, and I thought I would share something I learned recently that relates to the effect of physical activity on the progression of Alzheimer’s disease. Scientists ...

Novo Nordisk won't add Alzheimer's disease to the list of conditions its blockbuster diabetes and weight-loss drugs, Ozempic and Wegovy, can treat, despite high hopes and two years of study. The ...

Novo Nordisk announced Monday that in two closely watched studies, an oral version of semaglutide — the active ingredient in weight loss drugs — failed to help slow the progression of Alzheimer’s. The ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer's disease in closely watched trials, Novo Nordisk said Monday ...